JP2020506903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506903A5 JP2020506903A5 JP2019538585A JP2019538585A JP2020506903A5 JP 2020506903 A5 JP2020506903 A5 JP 2020506903A5 JP 2019538585 A JP2019538585 A JP 2019538585A JP 2019538585 A JP2019538585 A JP 2019538585A JP 2020506903 A5 JP2020506903 A5 JP 2020506903A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- pain
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- -1 1,1,1,3,3,3-hexafluoropropan-2-yl- Chemical group 0.000 claims 12
- 201000001119 neuropathy Diseases 0.000 claims 10
- 230000007823 neuropathy Effects 0.000 claims 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010028813 Nausea Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 201000002661 Spondylitis Diseases 0.000 claims 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000008693 nausea Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 102100029814 Monoglyceride lipase Human genes 0.000 claims 2
- 101710116393 Monoglyceride lipase Proteins 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 claims 2
- 208000004078 Snake Bites Diseases 0.000 claims 2
- 208000029033 Spinal Cord disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 206010004398 benign neoplasm of skin Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- WAKAFAWQLGONBP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(4-fluorophenyl)sulfonyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate Chemical compound FC1=CC=C(C=C1)S(=O)(=O)N1CCOC2(C1)CCN(CC2)C(=O)ON1C(CCC1=O)=O WAKAFAWQLGONBP-UHFFFAOYSA-N 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- UBTPQYKKARKUHR-CYBMUJFWSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl (3R)-3-[benzenesulfonyl(methyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound CN([C@H]1COC2(C1)CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)S(=O)(=O)C1=CC=CC=C1 UBTPQYKKARKUHR-CYBMUJFWSA-N 0.000 claims 1
- BNWWKJLMYVIPBW-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 2-[6-(difluoromethyl)pyridin-3-yl]oxy-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound FC(C1=CC=C(C=N1)OC1CC2(C1)CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)F BNWWKJLMYVIPBW-UHFFFAOYSA-N 0.000 claims 1
- JFFVJFKQYZTZMB-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-(4-cyanophenyl)-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(#N)C1=CC=C(C=C1)C1COC2(C1)CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F JFFVJFKQYZTZMB-UHFFFAOYSA-N 0.000 claims 1
- OVKLDGVHWSSHGP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[3-(trifluoromethoxy)phenyl]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound FC(OC=1C=C(C=CC=1)C1COC2(C1)CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)(F)F OVKLDGVHWSSHGP-UHFFFAOYSA-N 0.000 claims 1
- ABTCMVPMGZPSEI-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 3-[methyl(1,3-thiazol-2-ylsulfonyl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound CN(C1COC2(C1)CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F)S(=O)(=O)C=1SC=CN=1 ABTCMVPMGZPSEI-UHFFFAOYSA-N 0.000 claims 1
- OYEKKUGANYGFQY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 4-pyrazin-2-ylsulfonyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate Chemical compound N1=C(C=NC=C1)S(=O)(=O)N1CCOC2(C1)CCN(CC2)C(=O)OC(C(F)(F)F)C(F)(F)F OYEKKUGANYGFQY-UHFFFAOYSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 claims 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000004020 Brain Abscess Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000036166 Classic glucose transporter type 1 deficiency syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000010772 Dog disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000009139 Gilbert Disease Diseases 0.000 claims 1
- 208000022412 Gilbert syndrome Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108700006771 Glut1 Deficiency Syndrome Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000003423 Mucocele Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000003589 Spider Bites Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000010641 Tooth disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000026663 encephalopathy due to GLUT1 deficiency Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000026320 liver hemangioma Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007771 sciatic neuropathy Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000004706 scrotum Anatomy 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 0 CC[U]=*[C@@](C)(CCC1(CC*(CC(O*)=O)CC1)C1)C=CCCCC1(C)N Chemical compound CC[U]=*[C@@](C)(CCC1(CC*(CC(O*)=O)CC1)C1)C=CCCCC1(C)N 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449242P | 2017-01-23 | 2017-01-23 | |
| US62/449,242 | 2017-01-23 | ||
| PCT/IB2018/050128 WO2018134698A1 (en) | 2017-01-23 | 2018-01-09 | Heterocyclic spiro compounds as magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506903A JP2020506903A (ja) | 2020-03-05 |
| JP2020506903A5 true JP2020506903A5 (enExample) | 2021-02-12 |
Family
ID=61028112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538585A Withdrawn JP2020506903A (ja) | 2017-01-23 | 2018-01-09 | Ｍａｇｌ阻害薬としての複素環式スピロ化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180208608A1 (enExample) |
| EP (1) | EP3571202B1 (enExample) |
| JP (1) | JP2020506903A (enExample) |
| KR (1) | KR20190097242A (enExample) |
| CN (1) | CN110198944A (enExample) |
| AU (1) | AU2018208848A1 (enExample) |
| BR (1) | BR112019014099A2 (enExample) |
| CA (1) | CA3050853A1 (enExample) |
| IL (1) | IL267781A (enExample) |
| MX (1) | MX2019008690A (enExample) |
| RU (1) | RU2726631C1 (enExample) |
| SG (1) | SG11201906427QA (enExample) |
| TW (1) | TWI665199B (enExample) |
| WO (1) | WO2018134698A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| AU2017290362B2 (en) | 2016-07-01 | 2021-08-05 | Pharmacosmos Holding A/S | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| BR112019014688A2 (pt) * | 2017-01-20 | 2020-02-18 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| CN111148746B (zh) * | 2017-09-29 | 2022-08-05 | 武田药品工业株式会社 | 杂环化合物 |
| US10662159B2 (en) * | 2017-11-22 | 2020-05-26 | Makscientific, Llc | ABHD6 and dual ABHD6/MGL inhibitors and their uses |
| CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
| KR20210033504A (ko) * | 2018-07-19 | 2021-03-26 | 화이자 인코포레이티드 | Magl 억제제로서 헤테로환형 스피로 화합물 |
| CN120817904A (zh) | 2018-08-24 | 2025-10-21 | 法码科思莫斯有限公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
| MA53722A (fr) | 2018-09-28 | 2022-03-30 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
| JP2022509206A (ja) * | 2018-11-28 | 2022-01-20 | ハー・ルンドベック・アクチエゼルスカベット | Ｍａｇｌ阻害剤による疾病の治療方法 |
| CN109485656A (zh) * | 2018-12-17 | 2019-03-19 | 上海药明康德新药开发有限公司 | 3-氧亚基-7-氧杂-2,10-二氮杂螺[4.6]十一烷-10-甲酸叔丁酯的制法 |
| WO2020154683A1 (en) * | 2019-01-25 | 2020-07-30 | Lundbeck La Jolla Research Center, Inc. | Methods of treating disease with magl inhibitors |
| KR20220034104A (ko) * | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 신규 헤테로고리 화합물 |
| CN114555596B (zh) | 2019-09-30 | 2025-02-25 | 詹森药业有限公司 | 放射性标记的mgl pet配体 |
| JP7729831B2 (ja) * | 2020-03-26 | 2025-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子としてのアミノシクロブタン |
| AU2021270664B2 (en) * | 2020-05-12 | 2024-05-30 | Beijing Greatway Pharmaceutical Technology Co., Ltd. | Compound for adjusting activity of NMDA receptor, and pharmaceutical composition and use thereof |
| EP4217062B1 (en) | 2020-09-22 | 2024-10-09 | JANSSEN Pharmaceutica NV | Cyclobutyl amide monoacylglycerol lipase modulators |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US11434222B2 (en) * | 2020-11-13 | 2022-09-06 | H. Lundbeck A/S | MAGL inhibitors |
| WO2022135462A1 (zh) * | 2020-12-22 | 2022-06-30 | 鲁南制药集团股份有限公司 | Magl抑制剂的医药用途 |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN119137114A (zh) | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273659A1 (en) | 1986-12-27 | 1988-07-06 | Takeda Chemical Industries, Ltd. | Azaspiro compounds, their production and use |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| JPH10503768A (ja) | 1994-08-02 | 1998-04-07 | メルク シヤープ エンド ドーム リミテツド | アゼチジン、ピロリジンおよびピペリジン誘導体 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1182193A4 (en) | 1999-04-09 | 2002-09-11 | Mochida Pharm Co Ltd | REMEDIES FOR NEUROGENIC PAIN |
| CN1368848A (zh) | 1999-08-13 | 2002-09-11 | 阿温提斯作物科学有限公司 | 用作农药的杂环螺环化合物 |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| ES2279837T3 (es) | 2000-11-20 | 2007-09-01 | Scios Inc. | Inhibidores de tipo piperidina/piperazina de la quinasa p38. |
| DK1390372T3 (da) | 2001-05-14 | 2008-09-15 | Hoffmann La Roche | 1-oxa-3,9-diaza-spiro '5,5]undecan-2-on-derivater og anvendelse deraf som neurokininreceptorantagonist |
| EA200701782A3 (ru) | 2003-04-24 | 2008-04-28 | Инсайт Корпорейшн | Производные азаспироалканов в качестве ингибиторов металлопротеаз |
| CA2537185A1 (en) | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
| SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
| JP3912400B2 (ja) | 2004-03-30 | 2007-05-09 | 株式会社デンソー | 圧力センサ |
| ES2370788T3 (es) | 2005-02-07 | 2011-12-22 | Aerocrine Ab | Controlar flujo de aliento exhalado durante análisis. |
| US7786046B2 (en) | 2005-05-25 | 2010-08-31 | Basf Aktiengesellschaft | Benzoyl-substituted serineamides |
| CN101228133A (zh) | 2005-05-25 | 2008-07-23 | 巴斯福股份公司 | 杂芳酰基取代的丝氨酸酰胺 |
| KR20080027908A (ko) | 2005-06-30 | 2008-03-28 | 프로시디온 리미티드 | Ｇｐｃｒ 효능제 |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| ES2483866T3 (es) | 2006-12-05 | 2014-08-08 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1 |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CN102015677A (zh) | 2007-04-20 | 2011-04-13 | 先灵公司 | 嘧啶酮衍生物及其使用方法 |
| EP2058306A1 (en) | 2007-11-08 | 2009-05-13 | Schwarz Pharma Ag | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| US8822480B2 (en) | 2008-07-16 | 2014-09-02 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
| WO2010049146A1 (en) | 2008-10-29 | 2010-05-06 | Grünenthal GmbH | Substituted spiroamines |
| US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| BRPI0923819B1 (pt) | 2008-12-24 | 2021-11-09 | Bial-Portela & Ca, S.A. | Compostos inibidores de hidrolase amida de ácidos graxos, composições e usos dos mesmos |
| US8415341B2 (en) | 2009-04-22 | 2013-04-09 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| CA2759604A1 (en) | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| TW201211053A (en) | 2010-05-10 | 2012-03-16 | Nissan Chemical Ind Ltd | Spiro compound and drug for activating adiponectin receptor |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| JP2013537920A (ja) | 2010-09-27 | 2013-10-07 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ阻害剤としてのオキソピペラジン−アゼチジンアミド及びオキソジアゼピン−アゼチジンアミド |
| CA2815353A1 (en) | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| EP2686325B1 (en) | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| JP2014159376A (ja) | 2011-06-17 | 2014-09-04 | Taisho Pharmaceutical Co Ltd | アザスピロアルカン化合物 |
| NZ627750A (en) * | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| WO2013131010A2 (en) | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2015104343A1 (en) | 2014-01-09 | 2015-07-16 | Proyecto De Biomedicina Cima, S.L. | New antifibrinolytic compounds |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| CN109496213B (zh) * | 2016-05-12 | 2022-03-04 | H.隆德贝克有限公司 | 螺环化合物及其制备和使用方法 |
-
2018
- 2018-01-09 JP JP2019538585A patent/JP2020506903A/ja not_active Withdrawn
- 2018-01-09 WO PCT/IB2018/050128 patent/WO2018134698A1/en not_active Ceased
- 2018-01-09 BR BR112019014099-9A patent/BR112019014099A2/pt not_active Application Discontinuation
- 2018-01-09 EP EP18701578.9A patent/EP3571202B1/en active Active
- 2018-01-09 AU AU2018208848A patent/AU2018208848A1/en not_active Abandoned
- 2018-01-09 SG SG11201906427QA patent/SG11201906427QA/en unknown
- 2018-01-09 CA CA3050853A patent/CA3050853A1/en not_active Abandoned
- 2018-01-09 RU RU2019123020A patent/RU2726631C1/ru active
- 2018-01-09 CN CN201880007992.7A patent/CN110198944A/zh active Pending
- 2018-01-09 KR KR1020197021451A patent/KR20190097242A/ko not_active Withdrawn
- 2018-01-09 MX MX2019008690A patent/MX2019008690A/es unknown
- 2018-01-18 TW TW107101775A patent/TWI665199B/zh not_active IP Right Cessation
- 2018-01-22 US US15/876,698 patent/US20180208608A1/en not_active Abandoned
-
2019
- 2019-06-03 US US16/429,678 patent/US10858373B2/en active Active
- 2019-07-01 IL IL267781A patent/IL267781A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506903A5 (enExample) | ||
| JP2020506899A5 (enExample) | ||
| US11746091B2 (en) | Cannabinoid receptor modulators | |
| JP2019526582A5 (enExample) | ||
| RU2726631C1 (ru) | Гетероциклические спиросоединения в качестве ингибиторов magl | |
| US9751859B2 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts | |
| JP5843861B2 (ja) | Ａｘｌ阻害剤としての薬学的に活性な化合物 | |
| JP6322205B2 (ja) | がん治療用のピリミジン−２，４−ジアミン誘導体 | |
| JP6661749B2 (ja) | Ｒｏｒガンマモジュレータとしての新規化合物 | |
| JP2022166179A (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| KR102591886B1 (ko) | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 | |
| TW201609706A (zh) | 胺基嘧啶基化合物 | |
| JP2014524451A (ja) | 二環式複素芳香族化合物 | |
| JP2010518026A5 (enExample) | ||
| KR20120030447A (ko) | Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴 | |
| PT2222675E (pt) | 5-anilinoimidazopiridinas e métodos de utilização | |
| JP2017500364A (ja) | セリン／トレオニンキナーゼ阻害剤 | |
| JP2011526926A (ja) | 置換二環式ヘテロ環化合物と使用方法 | |
| JP2006522035A (ja) | 置換ピラゾール | |
| JP2010504302A (ja) | ５−ｈｔ６アンタゴニストとしてのスルホニルピラゾリンカルボキサミジン誘導体 | |
| AU2018229493A1 (en) | Therapeutic compounds and uses thereof | |
| KR20170040299A (ko) | 이미다조피리다진 화합물 | |
| JP4988583B2 (ja) | 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしての新規アントラニルアミドピリジンウレア | |
| JP2019520366A (ja) | Ａｌｋ５抑制剤としての新規ピラゾール誘導体およびその用途 | |
| JP7043483B2 (ja) | 二環式プロリン化合物 |